Compare SGRY & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SGRY | GLPG |
|---|---|---|
| Founded | 2004 | 1999 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.1B |
| IPO Year | 2015 | 2005 |
| Metric | SGRY | GLPG |
|---|---|---|
| Price | $17.19 | $31.65 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 9 | 4 |
| Target Price | $27.44 | ★ $31.33 |
| AVG Volume (30 Days) | ★ 2.6M | 125.8K |
| Earning Date | 11-10-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,288,100,000.00 | $336,643,201.00 |
| Revenue This Year | $7.76 | $3.61 |
| Revenue Next Year | $8.16 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 10.14 | ★ 10.31 |
| 52 Week Low | $14.94 | $22.36 |
| 52 Week High | $26.16 | $37.78 |
| Indicator | SGRY | GLPG |
|---|---|---|
| Relative Strength Index (RSI) | 44.19 | 50.15 |
| Support Level | $16.71 | $30.97 |
| Resistance Level | $17.44 | $31.98 |
| Average True Range (ATR) | 0.63 | 0.56 |
| MACD | 0.30 | 0.15 |
| Stochastic Oscillator | 89.29 | 75.41 |
Surgery Partners Inc is a healthcare services company with an integrated outpatient delivery model focused on providing quality, cost-effective solutions for surgical and related ancillary care in support of both patients and physicians. It has one reportable segment: Surgical Facilities which includes the operation of ASCs, surgical hospitals, anesthesia services, and multi-specialty physician practices, which earns revenues from contracts with patients in which the performance obligations are to provide health care services.
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.